Market+ (iPhone)

Market+ (Android)

US STOCKS

FUNDS

FX & CRYPTO

SH/SZ-HK

HK STOCKS

IPO Plus - IPO

To-be Listed

	Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
No Upcoming IPO

Summary

We are a clinical-stage biopharmaceutical company committed to the discovery, acquisition, development and commercialization of differentiated targeted therapies to address unmet medical needs in cancer treatment. Since our inception in 2017, we have built a pipeline with 11 drug candidates, including Core Product TY-9591, six clinical stage products, and four preclinical stage products. We are currently conducting a pivotal Phase II clinical trial of TY-9591 monotherapy as first-line treatment of brain metastases from non-small cell lung cancer (“NSCLC”) with epidermal growth factor receptor (“EGFR”) mutations in China, as well as a registrational Phase III clinical trial of TY-9591 monotherapy as first-line treatment in locally advanced (stage IIIb or IV) or metastatic NSCLC with EGFR L858R mutation in China. THERE IS NO ASSURANCE THAT WE WILL ULTIMATELY BE ABLE TO DEVELOP AND MARKET OUR CORE PRODUCT OR ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY. Our Business Model Our core business model involves internally discovering, acquiring, developing, and commercializing small molecule drugs and other innovative drug species related to small molecule drugs to address unmet needs in cancer treatment, especially in lung cancer. We have developed in-house R&D capabilities that cover not only early-stage drug discovery, chemical synthesis and selection, but also clinical development and regulatory affairs. In addition, we have been actively seeking global and regional partnerships with leading pharmaceutical companies to maximize the clinical and commercial value of our drug candidates. As our Core Product TY-9591 enters pivotal clinical trial stage, we are in the process of establishing our in-house cGMP-compliant manufacturing facility in Huzhou, Zhejiang Province, which is expected to commence commercial-scale manufacturing by the end of 2025. We also plan to establish sales and marketing capabilities through a combination of in-house efforts and working with external partners to secure our success in commercializing this product in China. OUR DRUG CANDIDATES The field of cancer treatment has developed significantly in the past century. Conventionally, treatment methods such as surgery, radiotherapy, and chemotherapy have been widely utilized to fight against tumor cells, but they have been proven to be deficient due to side effects and limited efficacy. The development of targeted therapies, which target specific molecules, generally proteins, enzymes, a signaling pathway, or genetic changes that play a role in the spread of cancer, has embarked on a new era of cancer treatment with enhanced specificity and efficacy. For details on the history of cancer treatment development, see “Industry Overview — Major Indications.” Source: TYK Medicines-B (02410) Prospectus (IPO Date : 2024/08/12)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	WU Yusheng & Associates (Total share: 35.39%); (H share: 23.85%) Jiangsu Addor Equity Investment Fund Management Co.,Ltd. (Total share: 5.50%); (H share: 10.59%) HE Chao & Associates (Total share: 5.23%); (H share: 3.53%) Changxing Xingchang Industrial Investment Partnership (Limited Partnership) (Total share: 4.58%); (H share: 8.83%)
Directors	WU Yusheng (Chairman and Chief Executive Officer and Executive Director) JIANG Mingyu (Vice President and Executive Director and Secretary to the Board) DING Zhao (Non-Executive Director) GU Eric Hong (Non-Executive Director) HE Chao (Non-Executive Director) LI Jun (Non-Executive Director) MENG Xiaoying (Non-Executive Director) LENG Yuting (Independent Non-Executive Director) SHEN Xiuhua (Independent Non-Executive Director) XU Wenqing (Independent Non-Executive Director) ZHANG Senquan (Independent Non-Executive Director)
Company Secretary	JIANG Mingyu WONG Wing Yee
Principal Bankers	China CITIC Bank Corporation Limited China Construction Bank
Solicitors	JunHe LLP O Melveny & Myers LLP
Auditors	Ernst & Young
Registered Office	Room 1901, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.tykmedicines.com
Email Address	investors@tykmedicines.com
Tel No	(86 21) 6167-6766
Fax No	(86 21) 6010-7317

SITEMAP

AASTOCKS.com

Members

Forgot Password

About Us

Email: support@aastocks.com

AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.

Disclaimer

You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.